Medical Polyoxymethylene Market Is Expected To Reach Revenue Of USD 253.5 Mn By 2033, at 7.4 % CAGR: Dimension Market Research
May 22, 2024 12:49 ET
|
Dimension Market Research
New York, May 22, 2024 (GLOBE NEWSWIRE) -- Market Overview The Medical Polyoxymethylene Market size is expected to reach USD 133.6 million by 2024 and is further anticipated to value USD 253.5...
Bion Gives Company Update
May 22, 2024 10:55 ET
|
BION ENVIRONMENTAL TECHNOLOGIES INC
New York, NY, May 22, 2024 (GLOBE NEWSWIRE) -- Bion Environmental Technologies, Inc. (OTC QB: BNET), a leader in advanced livestock waste treatment technology and premium sustainable beef, gave the...
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
May 20, 2024 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new...
Southeast Detox GA: Award Winning Suboxone Treatment Center in Rome, GA
May 16, 2024 09:00 ET
|
Southeast Detox GA
Rome, GA, May 16, 2024 (GLOBE NEWSWIRE) -- Southeast Detox GA, a leading inpatient alcohol and drug addiction rehab center, is excited to announce that its Rome Georgia in-patient detox facility has...
CryoMass Partners with Cannabis Powerhouse LEEF to Deploy Its Cryo Separation Technology
May 16, 2024 07:10 ET
|
Cryomass Technologies
CryoMass announced the sale of its second CryoSift Separator™ production model for US$1.2 million.
Venture Partnership: Leading Medical Recruitment Agency Secures Coveted Framework Award
May 15, 2024 09:00 ET
|
Venture Partnership
Uxbridge, England, May 15, 2024 (GLOBE NEWSWIRE) -- Venture Partnership, a leading recruitment agency focused on providing permanent and locum doctor staffing solutions to the primary, acute, and...
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
May 14, 2024 16:15 ET
|
Lumos Pharma, Inc.
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201...
CryoMass Announces Sale of First Production Model to be deployed in Canada
May 14, 2024 07:10 ET
|
Cryomass Technologies
The transaction we are announcing today is the first of such Unit sales for CAD$1.62 million, which will be deployed in Canada.
Pacific Health Care Organization, Inc. Reports its First Quarter 2024 Results
May 13, 2024 20:22 ET
|
Pacific Health Care Organization, Inc.
Irvine, May 13, 2024 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission (the “Commission”) its...
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
May 09, 2024 14:51 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first...